News

The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetic profile of GFB-887 in healthy volunteers and in patients with chronic kidney disease. Topline safety data from

The venetoclax, obinutuzumab combination met the primary endpoint of the late-stage trial called CLL14, which was investigator-assessed progression-free survival (PFS). The combination therapy, which was administered for a

The trial is a multi-center, open-label, and multi-dose Phase Ib/II study that aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor efficacy of the combination in advanced

ADPKD is the most common inherited form of kidney disease affecting approximately 140,000 patients in the United States.  It is characterized by the development of pathologic fluid-filled cysts

Emgality, which is an advanced therapeutic approach for the neurologic disease, is claimed to be the first and only calcitonin gene-related peptide (CGRP) antibody approved by the FDA

The approval for ZYNTEGLO is for the treatment of TDT in patients 12 years and older who do not have a β0/β0 genotype and for those who are

The FDA initially approved Zerbaxa in 2014 to treat complicated intra-abdominal infections and for complicated urinary tract infections. “A key global challenge we face as a public health

The results were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results from the trial showed a statistically-significant and

The Kisqali combination therapy, which was evaluated in both pre- and perimenopausal women in the late-stage trial called MONALEESA-7, delivered statistically significant overall survival (OS) results in comparison